BioXcel Therapeutics issues warrants to purchase 1.35M shares at $0.01 per share under credit amendment

BioXcel Therapeutics, Inc.

On April 15, 2026, BioXcel Therapeutics granted lenders warrants to purchase up to 1,353,729 shares of common stock at an exercise price of $0.01 per share.
The warrants were issued pursuant to the Ninth Amendment to the Credit Agreement and Guaranty, dated April 19, 2022.
The Company also entered into a Fourth Amended and Restated Registration Rights Agreement with the lenders to register shares underlying the warrants.
The lenders include entities such as Oaktree-TCDRS Strategic Credit, LLC, Oaktree Specialty Lending Corporation, and others.
The warrants expire on the seventh anniversary of issuance and were issued in reliance on Section 4(a)(2) of the Securities Act.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

BioXcel Therapeutics, Inc. issued 1,353,729 shares of common stock of warrant to the lenders under the Ninth Amendment for exercise price of $0.01 per share.

Security: warrant
Shares: 1,353,729 shares of common stock
Purchaser: the lenders under the Ninth Amendment
Consideration: exercise price of $0.01 per share

Exact text from the filing

On April 15, 2026, the Company granted the lenders under the Ninth Amendment (the "Lenders") warrants to purchase up to 1,353,729 shares of common stock at an exercise price of $0.01 per share (the "Amendment Warrants").

View on SEC.gov

Browse all equity issuances →

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-044952

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.